Novartis in Slovenia is once again opening its doors to students and is calling for applications for BioCamp
- BioCamp is a scientific event designed to bring together students of science, economics and engineering with renowned experts and leading executives.
- The BioCamp 2022 online event will take place from September 26 to 30 and will accept applications until May 31, 2022. The focus of the event will be on new methods of treatment in the age of the metaverse.
- BioCamp is an award-winning event that provides top students with a unique insight into the world of research and the international business environment of the pharmaceutical industry. Novartis in Slovenia is recognized for its talent acquisition and management practices.
Novartis in Slovenia is organizing the 12th annual BioCamp, a scientific event aimed at bringing together promising students, academic institutions, and the economy. This award-winning practice allows science, economics and engineering students from all over the world to gain insight into the pharmaceutical industry, offers a unique platform for networking, and opens doors to career opportunities.
"As one of the largest and most well-known employers in Slovenia, we understand that innovative, inquisitive, and agile talent is key to the success of our business and to fulfilling our mission of improving the quality of life for people around the world. BioCamp is a unique event that brings together some of the key strategic focuses of Novartis in Slovenia – supporting innovation, fostering the development of young professionals, and connecting the economic and academic spheres. The many years of tradition and success of the project prove that this way of learning about the industry is close to the hearts of young people, and at the same time it allows us as a company to present current challenges in the pharmaceutical industry and the values of Novartis in Slovenia to top students, future professionals and managers," said Dr. Janko Ignjatović, Development Project Manager at Development Center Slovenia and Chair of the BioCamp organizational committee.
The focus of this year's event will be new treatments and reimagining medicine in the age of the metaverse. The event will be held online and will incorporate state-of-the-art digital and technological solutions to expand networking and collaboration opportunities for participants. During the event, participants will have the opportunity to address real challenges in the pharmaceutical industry through lectures and workshops. They will develop solutions in teams with other students and present their knowledge and reasoning to a panel of experts.
"At BioCamp, I experienced the dynamic global environment of the pharmaceutical and biotech industry and had the opportunity to meet key experts from industry and academia. Immediately after BioCamp, I was offered a study exchange at the Sandoz Development Center in Ljubljana, where I now work as a research expert in pharmaceutical development. With the increasing competition on the job market, I advise young people to seize the opportunity and experience the world of pharmaceuticals, and at the same time show their potential to a prospective future employer," said Ognen Jakasanovski, a former BioCamp participant and now an associate of Novartis in Slovenia.
Over the eleven years, 392 young people from 31 countries have participated in BioCamp, and more than 45 of them are now Novartis associates. Applications for the event are open until May 31, 2022, at www.lek.si/biocamp, where you can also find the schedule and more information.
Novartis is the leading provider of medicines in Slovenia, where Lek d.d., Novartis Pharma Services Inc. and Sandoz d.d., operate. Together we are building and maintaining the reputation of a dynamic, ethical, and trusted pharmaceutical company. Lek develops, manufactures, and markets effective, safe, and high-quality medicines and active pharmaceutical ingredients. With our knowledge, quality, and experience we have gained an important role in Novartis' organizational structure, especially in the Novartis Operations, Global Drug Development and the generic division Sandoz. We are the leading Sandoz development center, and one of the key development sites for technologically complex projects. We invest a great deal in the development, education, and training of our employees. Novartis invested in Slovenia more than EUR 3 billion since 2003.
About Sandoz
Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2021 sales of USD 9.6 billion.
About Novartis
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
This press release contains statements and forecasts of future business operations.The forecasts include estimates based on all the information currently available to us. Should these forecasts prove unreliable, the actual results of business operations could be different from those expected.
For further information, please contact:
Gregor Makuc
Communication & External Engagement
Lek Pharmaceuticals d.d.
Telephone: 01 580 22 43
gregor.makuc@sandoz.com
